COVID-19 With Convalescent Plasma

Southeast University, China78 enrolled

Overview

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19 Convalescent Plasma Treatment

Interventions

convalescent plasmaBIOLOGICAL

convalescent plasma was get from the patients who recovery from COVID-19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. \> 18 years of age; 2. laboratory-confirmed diagnosis of COVID-19; 3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula\[HFNC\], noninvasive mechanical ventilation \[NIV\], and invasive mechanical ventilation \[IMV\]). Exclusion Criteria: * no

Locations (1)

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

28-day mortality

the mortality from ICU admission to 28 days after admission

Time frame: 28 days

Secondary Outcomes

SARS-CoV-2 negative conversion rate

SARS-CoV-2 viral shedding

Time frame: up to 60 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.